Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set

Annals of the Rheumatic Diseases

Volumn 71, Issue 3, 2012, Pages 358-362

  FitzGerald, Oliver ^a   Helliwell, Philip ^b   Mease, Philip ^c   Mumtaz, Aizad ^a   Coates, Laura ^b   Pedersen, Ronald ^d   Nab, Henk ^d   Molta, Charles ^d  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT;

ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY INDEX FOR PSORIATIC ARTHRITIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG RESPONSE; ENTHESITIS; HUMAN; INTERMETHOD COMPARISON; INTERVENTION STUDY; JOINT SWELLING; MAJOR CLINICAL STUDY; MODIFIED COMPOSITE PSORIATIC DISEASE ACTIVITY INDEX; POST HOC ANALYSIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SCORING SYSTEM;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PAIN MEASUREMENT; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84857235524     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200093     Document Type: Article

References (13)

1. Helliwell PS, Wright V. Psoriatic arthritis: clinical features. In: Klippel JH DP, ed. Rheumatology. London: Mosby 1998:6. 21.1-6.21.8.
2. McCarey D, McInnes IB. Psoriatic arthritis: current topics. Curr Rheumatol Rep 2007;9:442-8. (Pubitemid 350305200)
3. Setty A R, Choi HK. Psoriatic arthritis epidemiology. Curr Rheumatol Rep 2007;9:449-54. (Pubitemid 350305201)
4. Felson D T, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
5. van der Heijde D M, van't Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
6. Clegg D O, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013-20.
7. Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011;70:272-7.
8. Ritchlin C T, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
9. Eberl G, Studnicka-Benke A, Hitzelhammer H, et al. Development of a Disease Activity index for the assessment of REactive Arthritis (DAREA). Rheumatology (Oxford) 2000;39:148-55. (Pubitemid 30139347)
10. Nell-Duxneuner V P, Stamm TA, Machold KP, et al. Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis 2010;69:546-9.
11. Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69:1441-7.
12. Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010;340:c147.
13. Helliwell P S, FitzGerald O, Strand V, et al. Composite measures in psoriatic arthritis. Report from the GRAPPA 2009 annual meeting. J Rheumatol 2011; (In Press).